SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

10 Aug 2022 Evaluate
Net sales declined -17.09%  to  Rs. 629.37 million from Rs. 759.09 millions.A radical decline of -97.35% was reported in the net profit of the company for the quarter ended June 2022 to Rs. 5.12  millions from Rs. 193.49 millions.The Operating Profit of the company witnessed a decrease to 31.23 millions from 280.49 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 629.37 759.09 -17.09 629.37 759.09 -17.09 3186.67 2552.07 24.87
Other Income 36.47 49.22 -25.90 36.47 49.22 -25.90 126.40 115.21 9.71
PBIDT 31.23 280.49 -88.87 31.23 280.49 -88.87 782.09 852.30 -8.24
Interest 4.98 3.70 34.59 4.98 3.70 34.59 15.62 18.40 -15.11
PBDT 26.25 276.79 -90.52 26.25 276.79 -90.52 766.47 833.90 -8.09
Depreciation 19.58 19.33 1.29 19.58 19.33 1.29 76.73 73.94 3.77
PBT 6.67 257.46 -97.41 6.67 257.46 -97.41 689.74 759.96 -9.24
TAX 1.55 63.97 -97.58 1.55 63.97 -97.58 167.28 205.28 -18.51
Deferred Tax -7.20 3.97 -281.36 -7.20 3.97 -281.36 -4.22 14.58 -128.94
PAT 5.12 193.49 -97.35 5.12 193.49 -97.35 522.46 554.68 -5.81
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 4.96 36.95 -86.57 4.96 36.95 -86.57 24.54 33.40 -26.51

NGL Fine-Chem Share Price

3189.20 -11.85 (-0.37%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: